Table 1.
Pretreatment characteristics of 154 HIV-infected women who initiated therapy in Johannesburg, South Africa, by single-dose nevirapine (sdNVP) exposure status.
| Characteristic | sdNVP- exposed women (n = 94) | sdNVP- unexposed women (n = 60) | P |
|---|---|---|---|
| Age, mean years ± SD | 30.9 ± 5.15 | 29.3 ± 4.93 | .05 |
| Interval since most recent pregnancy, median months (IQR) | 24.8 (20.4–29.9) | 19.1 (14.5–26.3) | <.001 |
| Median parity (IQR) | 2 (1–3) | 2 (1–3) | .72 |
| WHO stage of HIV infection | |||
| 1 | 22 (23.4) | 11 (18.3) | |
| 2 | 15 (16.0) | 12 (20.0) | |
| 3 | 56 (59.6) | 35 (58.3) | |
| 4 | 1 (1.1) | 1 (1.7) | .75 |
| CD4 cell count, median cells/mm3 (IQR) | 159 (85–210) | 177 (130–241) | .11 |
| HIV RNA level, median copies/mL (IQR) | 96,150 (39,100–299,500) | 115,500 (45,600–546,000) | .30 |
| Completion of high school | 36 (38.3) | 18 (30.0) | .29 |
| Employment | 38 (40.4) | 10 (16.7) | .002 |
| Married status | 19 (20.2) | 7 (11.7) | .17 |
| HIV status was disclosed to husband or partner | 60 (63.8) | 34 (56.7) | .37 |
| Presence reported of household members who do not know subject’s HIV status | 36 (38.3) | 17 (28.3) | .20 |
| Other household members are known to have HIV infection | 55 (58.5) | 46 (76.7) | .01 |
| Others in household taking antiretroviral therapy | 31 (33.0) | 23 (38.3) | .50 |
| Child in household known to have HIV infection | 26 (27.7) | 19 (31.7) | .59 |
| Characteristics of home | |||
| Inside tap present | 47 (50.0) | 28 (46.7) | .69 |
| Electricity present | 82 (87.2) | 47 (78.3) | .14 |
| Refrigerator present | 70 (74.5) | 31 (51.7) | .004 |
| Radio present | 77 (81.9) | 47 (78.3) | .58 |
| Television present | 82 (87.2) | 42 (70.0) | .009 |
| Reported alcohol use | 22 (23.4) | 12 (20.0) | .62 |
| Reported traditional medicine use | 11 (11.7) | 7 (11.7) | .98 |
| Initial treatment regimen | |||
| NVPa | 74 (78.7) | 44 (73.3) | |
| Efavirenz | 20 (21.3) | 16 (26.7) | .44 |
| Good adherence to treatment, b proportion of patients (%) | |||
| First assessment after treatment | 87/90 (96.7) | 53/57 (93.0) | .31 |
| Week 24 | 76/82 (92.7) | 47/51 (92.2) | .91 |
| Week 52 | 58/66 (87.9) | 39/45 (86.7) | .85 |
NOTE. Data are no. (%) of women, unless otherwise indicated. Ninety-four women had been exposed to single-dose NVP (sdNVP) 18–36 months earlier, and 60 had not been exposed but had been pregnant 12–36 months earlier. IQR, interquartile range; WHO, World Health Organization.
a
Five sdNVP-exposed women and 8 sdNVP-unexposed women initially started receiving nevirapine and had their regimens switched to efavirenz during the course of the study.
b
Defined as >80% pill count reconciliation.